Antibody

α-synuclein (LB509)

Tools

Back to the Top

Clonality: monoclonal
Host: Mouse
Isotype: IgG1
Methods: IH, WB
Source: Zymed/ Invitrogen
Cat# 18-0215
References:
Paleologou, 2010
Lo Bianco, 2008
Ihara, 2007
Josephs, 2007
Tsigelny, 2007
Sherer, 2002
Formulation: IHC concentrate; available diluted ready-to-use cat # 08-1215
Reactivity:
Reacts in: Human

Immunogen/Epitope

immunogen = Lewy bodies purified from patients suffering from DLB

Specificity

α-synuclein; not β- or γ-synuclein

Comments / Questions

Make a comment or submit a question

To make a comment you must login or register.

Comments on this content

No Available Comments

References

Paper Citations

  1. . Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci. 2010 Mar 3;30(9):3184-98. PubMed.
  2. . Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J Clin Invest. 2008 Sep;118(9):3087-97. PubMed.
  3. . Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity. Neuron. 2007 Feb 15;53(4):519-33. PubMed.
  4. . Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol. 2008 Feb;63(2):204-12. PubMed.
  5. . Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. FEBS J. 2007 Apr;274(7):1862-77. PubMed.
  6. . An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci. 2002 Aug 15;22(16):7006-15. PubMed.

Further Reading